Search results
Showing 151 to 157 of 157 results for fibrosis
NICE's support for rebuilding capacity in non-COVID health services
Director of our Centre for Guidelines, Paul Chrisp, discusses how NICE can help the NHS and wider care sector restore services most affected by the COVID-19 pandemic
NICE backed award for physiotherapist helping to improve patients' quality of life
Laura McNeillie picks up NICE award at Chief Allied Health Professions Officer’s awards
Today (Thursday 29 November), NICE opens a public consultation on its preliminary recommendations on the NHS use of the drug, pirfenidone (known commercially as Esbriet). The draft guidance assesses whether it should be recommended for use in people who have the lung condition, idiopathic pulmonary fibrosis.
NICE broadens recommendation on chronic lung disease treatment
Antibiotics should not be issued as first line of treatment for a cough, says NICE and PHE
People should take honey or cough medicines instead but speak to their GP if it persists for longer than three weeks
NICE has today (9 April 2020) published 3 new rapid guidelines on the care of patients with suspected and confirmed COVID-19, and in patients without COVID-19. The guidelines have been designed to maximise the safety of patients whilst enabling services to make the best use of NHS resources.
They cover the management of patients with severe asthma, pneumonia, rheumatological autoimmune, inflammatory and metabolic bone disorders and the management of COVID-19 symptoms in the community.